Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: Redox proteomics analysis of human brain
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
DS is the most frequent genetic cause of intellectual disability characterized by the anomalous presence of three copies of chromosome 21. One of the peculiar features of DS is the onset of Alzheimer’s disease neuropathology after the age of 40 years characterized by deposition of senile plaques and neurofibrillary tangles. Growing studies demonstrated that increased oxidative damage, accumulation of unfolded/damaged protein aggregates and dysfunction of intracellular degradative system are key players in neurodegenerative processes. In this study, redox proteomics approach was used to analyze the frontal cortex from DS subjects under the age of 40 compared with age-matched controls, and proteins found to be increasingly carbonylated were identified. Interestingly, our results showed that oxidative damage targets specifically different components of the intracellular quality control system such as GRP78, UCH-L1, V0-ATPase, cathepsin D and GFAP that couples with decreased activity of the proteasome and autophagosome formation observed. We also reported a slight but consistent increase of Aβ 1–42 SDS- and PBS-soluble form and tau phosphorylation in DS versus CTR. We suggest that disturbance in the proteostasis network could contribute to the accumulation of protein aggregates, such as amyloid deposits and NFTs, which occur very early in DS. It is likely that a sub-optimal functioning of degradative systems occur in DS neurons, which in turn provide the basis for further accumulation of toxic protein aggregates. The results of this study suggest that oxidation of protein members of the proteostatis network is an early event in DS and might contribute to neurodegenerative phenomena.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophagy Is Activated for Cell Survival after Endoplasmic ReticulumStress
Ogata, M., Hino, S.-I., Saito, A., Morikawa, K., Kondo, S., Kanemoto, S., Murakami, T., Taniguchi, M., Tanii, I., Yoshinaga, K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01453-06 · Cited by 1,832
Zoncu, R., Bar-Peled, L., Efeyan, A., Wang, S., Sancak, Y., & Sabatini, D. M. (2011) · Science · doi:10.1126/science.1207056 · Cited by 1,673
One step at a time: endoplasmic reticulum-associated degradation
Vembar, S. S., & Brodsky, J. L. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2546 · Cited by 1,299 · cited 1×
“Upon activation of ER-stress response, ERADmediates ubiquitination of misfolded proteins, which occur in the cytoplasm [38].”
BackgroundLee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.008 · Cited by 1,212 · cited 1×
“Restoration of lysosomal function by genetic intervention was able to prevent neuropathology and cognitive deficits of an AD mouse model [61,62].”
BackgroundRamirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
Self-citationYoshida, H. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05639.x · Cited by 1,086 · cited 6×
“UPR is a primary line of defense of the cell against toxic accumulation of misfolded proteins [24,36] and UPR occurs mainly in three steps: 1) up-regulation ofmolecular chaperones to assist in protein refolding; 2) arrest of further protein synthesis; and 3) ubiquitination of misfolded proteins and their translocation…”
BackgroundInfluentialMiddeldorp, J., & Hol, E. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.01.005 · Cited by 1,080 · cited 1×
“GFAP is expressed in activated astrocytes, where it is thought to help maintain mechanical strength, as well as the shape of cells [65].”
BackgroundImpaired Proteasome Function in Alzheimer's Disease
Keller, J. N., Hanni, K. B., & Markesbery, W. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750436.x · Cited by 848 · cited 1×
“[27].”
Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro
Busciglio, J., & Yankner, B. A. (1995) · Nature · doi:10.1038/378776a0 · Cited by 741 · cited 1×
“Increased production of ROS is also accompanied by mitochondrial dysfunction, both of which are considered to be a trigger for development of AD in DS population [17].”
Background
Cited by
Mechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases
Nixon, R. A., & Rubinsztein, D. C. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00757-5 · Cited by 435
“…from the accumulated pathogenic protein (for example, amyloid-β, α-synuclein); however, hydrolytic failure generates numerous damaging derivatives, most notably oxidized lipids and proteins that further inhibit hydrolases by oxidizing or otherwise damaging resident proteins 24,36–38, 248, 249 .”
Butterfield, D. A., Di Domenico, F., & Barone, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.010 · Cited by 402
Self-citationDementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Self-citationTramutola, A., Triplett, J. C., Di Domenico, F., Niedowicz, D. M., Murphy, M. P., Coccia, R., Perluigi, M., & Butterfield, D. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13037 · Cited by 347
Self-citationPerluigi, M., Di Domenico, F., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.014 · Cited by 339
Self-citationAging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
Head, E., T. Lott, I., M. Wilcock, D., & A. Lemere, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151020114607 · Cited by 289
Self-citationPerluigi, M., Di Domenico, F., & Butterfield, D. A. (2024) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 282
Self-citationCellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., & Broersen, K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190863 · Cited by 204
Colacurcio, D. J., Pensalfini, A., Jiang, Y., & Nixon, R. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.001 · Cited by 167
The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders
Vidoni, C., Follo, C., Savino, M., Melone, M. A. B., & Isidoro, C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21394 · Cited by 164
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain
Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D. A., & Di Domenico, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.007 · Cited by 155
“proteasome, autophagy) in DS cases [12].”
InfluentialSelf-citationCorsetti, V., Florenzano, F., Atlante, A., Bobba, A., Ciotti, M. T., Natale, F., Della Valle, F., Borreca, A., Manca, A., Meli, G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv059 · Cited by 129
Barone, E., Di Domenico, F., Mancuso, C., & Butterfield, D. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.018 · Cited by 127
Self-citationButterfield, D. A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.006 · Cited by 126
Self-citationDi Domenico, F., Barone, E., Perluigi, M., & Butterfield, D. A. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6759 · Cited by 114
Self-citationRedox proteomics and amyloid β-peptide: Insights into Alzheimer disease
Butterfield, D. A., & Boyd‐Kimball, D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14589 · Cited by 105
“Redox proteomics identified that brain-resident UCHL1 is oxidatively modified in FAD (Butterfield et al. 2006b), LAD (Castegna et al. 2002a; Choi et al. 2004; Sultana et al. 2006c), and DS (Di Domenico et al. 2013, 2014).”
BackgroundSelf-citationDi Domenico, F., Tramutola, A., Foppoli, C., Head, E., Perluigi, M., & Butterfield, D. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.009 · Cited by 89
“In agreement, studies from our laboratory demonstrated a tight association between reduced autophagosome formation and increased p-tau levels in DS individuals prior to and after AD development [16,49].”
BackgroundResultInfluentialSelf-citationDi Domenico, F., Pupo, G., Mancuso, C., Barone, E., Paolini, F., Arena, A., Blarzino, C., Schmitt, F. A., Head, E., Butterfield, D. A., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141254 · Cited by 75
Self-citationTargeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies.
Tramutola, A., Lanzillotta, C., & Di Domenico, F. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1244482 · Cited by 69
“the alteration of mTOR signaling is an early degenerating event in the brain that contributes to the early development of AD-like cognitive decline [10,27,115,116].”
BackgroundDi Domenico, F., Head, E., Butterfield, D. A., & Perluigi, M. (2014) · Advances in Geriatrics · doi:10.1155/2014/527518 · Cited by 50
Self-citationTramutola, A., Di Domenico, F., Barone, E., Arena, A., Giorgi, A., di Francesco, L., Schininà, M. E., Coccia, R., Head, E., Butterfield, D. A., et al. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6686 · Cited by 49
“Previous studies from our group demonstrate impairments of the proteasome system (17) and the reduction of autophagosome function in DS, before and after the development of AD, which suggests that accumulation of oxidized/misfolded protein is an early hallmark in DS brain (59).”
BackgroundSelf-citationLanzillotta, C., Tramutola, A., Di Giacomo, G., Marini, F., Butterfield, D. A., Di Domenico, F., Perluigi, M., & Barone, E. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.01.042 · Cited by 47
Self-citationAlzheimer’s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks
Castrillo, J. I., & Oliver, S. G. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2627-5_1 · Cited by 44
Tramutola, A., Pupo, G., Di Domenico, F., Barone, E., Arena, A., Lanzillotta, C., Broekaart, D., Blarzino, C., Head, E., Butterfield, D. A., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151105 · Cited by 40
“However, with the accumulation of oxidative damage over the lifespan and the consequent impairment of selected proteins [22, 26], as demonstrated by redox proteomics studies from our group, p53 transcriptional activity is increased and a pro-apoptotic phenotype prevails driving the accelerated…”
Self-citationPerluigi, M., Tramutola, A., Pagnotta, S., Barone, E., & Butterfield, D. A. (2020) · Antioxidants · doi:10.3390/antiox9090779 · Cited by 39
Self-citationProtto, V., Tramutola, A., Fabiani, M., Marcocci, M. E., Napoletani, G., Iavarone, F., Vincenzoni, F., Castagnola, M., Perluigi, M., Di Domenico, F., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8070972 · Cited by 36
Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials
Rueda Revilla, N., & Martínez-Cué, C. (2020) · Antioxidants · doi:10.3390/antiox9080692 · Cited by 35
Astrocytes in Down Syndrome Across the Lifespan
Ponroy Bally, B., & Murai, K. K. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.702685 · Cited by 35
Rastogi, M., Bartolucci, M., Nanni, M., Aloisio, M., Vozzi, D., Petretto, A., Contestabile, A., & Cancedda, L. (2024) · Neuron · doi:10.1016/j.neuron.2024.05.002 · Cited by 26
The fine-tuning of proteolytic pathways in Alzheimer’s disease
Cecarini, V., Bonfili, L., Cuccioloni, M., Mozzicafreddo, M., Angeletti, M., Keller, J. N., & Eleuteri, A. M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2238-6 · Cited by 21
Wu, Y., Mumford, P., Noy, S., Cleverley, K., Mrzyglod, A., Luo, D., van Dalen, F., Verdoes, M., Fisher, E. M. C., & Wiseman, F. K. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01632-8 · Cited by 16
A dynamic in vitro model of Down syndrome neurogenesis with trisomy 21 gene dosage correction
Bansal, P., Banda, E. C., Glatt-Deeley, H. R., Stoddard, C. E., Linsley, J. W., Arora, N., Deleschaux, C., Ahern, D. T., Kondaveeti, Y., Massey, R. E., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj0385 · Cited by 13
“Third, cellular stress pathways that are chronically and systemically active in DS ( 13 – 18 ) and likely play an important role in DS neurodegeneration ( 19 ) are also shared with human trisomies T13 and T18 ( 20 ).”
Metadata
- Authors
- Di Domenico, F., Coccia, R., Cocciolo, A., Murphy, M. P., Cenini, G., Head, E., Butterfield, D. A., Giorgi, A., Schinina, M. E., Mancuso, C., Cini, C., & Perluigi, M.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 1832
- Issue
- 8
- Pages
- 1249-1259
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W2018897386
- Cited by
- 134
- References
- 21
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.